iSpecimen (ISPC) - 2024 Q3 - Quarterly Report

Financing Activities - The company closed a private placement offering on December 1, 2021, for gross proceeds of approximately $21 million, after deducting$1.4 million for underwriting discounts and commissions [117]. - As of September 30, 2024, the company issued 199,004 shares of common stock for gross proceeds of $1,494,000 under the At the Market Offering Agreement [118]. - The company entered into a Note Purchase Agreement on September 19, 2024, for a loan of$1,000,000 with an interest rate of 18% per annum, and paid off the principal and accrued interest of $1,018,000 on October 31, 2024 [125][126]. - The company raised approximately$4,998,464 in a public offering on October 31, 2024, by issuing 132,814 shares of common stock at an offering price of $2.999 per share [127]. - Net cash provided by financing activities for the nine months ended September 30, 2024, was approximately$2,047,000, including $1,494,000 from the issuance of common stock [185]. Revenue and Sales Performance - Revenue decreased by approximately$116,000, or 4%, from approximately $2,778,000 for the three months ended September 30, 2023, to approximately$2,662,000 for the three months ended September 30, 2024 [152]. - Revenue increased by approximately $463,000, or 6$7,353,000 for the nine months ended September 30, 2023 to approximately $7,816,000 for the nine months ended September 30, 2024 [163]. - The average selling price per specimen decreased by$203, or 39%, from approximately $518 in the three months ended September 30, 2023, to approximately$315 in the three months ended September 30, 2024 [152]. - The average selling price per specimen increased by approximately $4, or 1$394 in the nine months ended September 30, 2023 to $398 in the nine months ended September 30, 2024 [163]. - Specimen count increased by 3,094, or 58$162,000, or 12%, from approximately $1,393,000 for the three months ended September 30, 2023, to approximately$1,554,000 for the three months ended September 30, 2024 [153]. - Cost of revenue increased by approximately $586,000, or 17$3,393,000 for the nine months ended September 30, 2023 to approximately $3,979,000 for the nine months ended September 30, 2024 [164]. - Total technology expenditures decreased by approximately$796,000, or 47%, from approximately $1,691,000 for the three months ended September 30, 2023, to approximately$895,000 for the three months ended September 30, 2024 [154]. - Total technology expenditure decreased by approximately $2,933,000, or 48$6,100,000 for the nine months ended September 30, 2023 to approximately $3,167,000 for the nine months ended September 30, 2024 [165]. - Sales and marketing expenses decreased by approximately$266,000, or 30%, from approximately $898,000 for the three months ended September 30, 2023, to approximately$632,000 for the three months ended September 30, 2024 [157]. - Supply development expenses decreased by approximately $101,000, or 54$186,000 for the three months ended September 30, 2023, to approximately $85,000 for the three months ended September 30, 2024 [158]. - Fulfillment costs decreased by approximately$23,000, or 5%, from approximately $472,000 for the three months ended September 30, 2023, to approximately$449,000 for the three months ended September 30, 2024 [159]. - General and administrative expenses decreased by approximately $470,000, or 10$4,522,000 for the nine months ended September 30, 2023 to approximately $4,052,000 for the nine months ended September 30, 2024 [172]. - Supply development expenses decreased approximately$381,000, or 48%, from approximately $801,000 for the nine months ended September 30, 2023 to approximately$420,000 for the nine months ended September 30, 2024 [170]. Cash Flow and Financial Position - Net cash used in operating activities was approximately $4,691,000 for the nine months ended September 30, 2024, compared to approximately$6,153,000 for the same period in 2023, reflecting a decrease of $1,462,000 or 24$591,812, or 25%, from $2,343,666 as of December 31, 2023 to$1,751,854 as of September 30, 2024 [174]. - Total changes in assets and liabilities were approximately $108,000, driven by a$503,000 decrease in accrued expenses and a $351,000 increase in accounts receivable [182]. - Net cash provided by investing activities for the nine months ended September 30, 2024, was approximately$2,053,000, primarily from $3,150,000 in proceeds from sales and maturities of available-for-sale securities [183]. - Net cash used in investing activities for the nine months ended September 30, 2023, was approximately$6,505,000, with $10,143,000 spent on available-for-sale securities [184]. Operational Challenges and Market Conditions - The company experienced delays in fulfilling purchase orders due to the ongoing war between Russia and Ukraine, impacting margins and resource allocation [134]. - As of September 30, 2024, supply sites in Russia were accessible, and most supply sites in Ukraine were reopened, but logistics remain challenging [135]. - The company has taken steps to address current market conditions, including reevaluating pricing and enhancing internal communications to accelerate the sales cycle [131]. - The company aims to improve liquidity to address financial obligations amid an industry-wide economic slowdown in life science research [133]. - The company experienced negative effects of inflation, particularly impacting employee salaries and supply costs, although specimen costs remained stable due to long-term vendor contracts [188][189]. Internal Controls and Governance - A material weakness in internal control over financial reporting was identified, related to sales tax obligations, prompting a remediation plan that began in Q2 2023 [197][198]. - The company is implementing a sales tax software solution to enhance the calculation, collection, and remittance of sales tax for future sales [199]. - Changes in the board of directors occurred on September 25, 2024, with three new directors appointed following the closing of a purchase agreement [208][209]. - The company intends to vigorously defend against a claim for$586,800 made by a former executive regarding unpaid bonuses and severance [203][204]. - Management believes that the unaudited condensed financial statements fairly present the company's financial position despite the identified material weakness [197]. Future Outlook and Strategic Initiatives - The company reported a significant increase in revenue, achieving $X million for the quarter, representing a Y$A million and $B million, indicating a growth rate of C$D million in revenue over the next fiscal year [214]. - The company is investing in R&D, allocating $E million towards the development of new technologies and products [214]. - Market expansion efforts are underway, with plans to enter F new markets by the end of the fiscal year [214]. - The company is considering strategic acquisitions to enhance its market position, with potential targets identified [214]. - A new marketing strategy has been implemented, aiming to increase brand awareness and customer engagement by G$H million annually [214]. - The management team emphasized a commitment to sustainability, with initiatives expected to reduce operational costs by I% over the next three years [214].